{"id":"https://openalex.org/W2481799548","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.tps5612","title":"A phase I/II study of the vascular disrupting agent BNC105P in combination with gemcitabine-carboplatin in partially platinum-sensitive ovarian cancer patients in first or second relapse: An international collaborative group trial of ANZGOG and HOG.","display_name":"A phase I/II study of the vascular disrupting agent BNC105P in combination with gemcitabine-carboplatin in partially platinum-sensitive ovarian cancer patients in first or second relapse: An international collaborative group trial of ANZGOG and HOG.","publication_year":2013,"publication_date":"2013-05-20","ids":{"openalex":"https://openalex.org/W2481799548","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.tps5612","mag":"2481799548"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2013.31.15_suppl.tps5612","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.tps5612","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.15_suppl.tps5612","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5060469120","display_name":"Danny Rischin","orcid":"https://orcid.org/0000-0002-3368-0386","observed_orcids":["https://orcid.org/0000-0002-3368-0386"]},"institutions":[{"id":"https://openalex.org/I2800555584","display_name":"Peter MacCallum Cancer Centre","ror":"https://ror.org/02a8bt934","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800555584"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Danny Rischin","raw_affiliation_strings":["Peter MacCallum Cancer Centre, Melbourne, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Peter MacCallum Cancer Centre, Melbourne, Australia","institution_ids":["https://openalex.org/I2800555584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067743297","display_name":"Daniela Elena Matei","orcid":"https://orcid.org/0000-0003-2169-5035","observed_orcids":["https://orcid.org/0000-0003-2169-5035"]},"institutions":[{"id":"https://openalex.org/I4394709130","display_name":"Indiana University School of Medicine","ror":"https://ror.org/02ets8c94","country_code":"US","type":"education","lineage":["https://openalex.org/I4394709130","https://openalex.org/I592451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniela Matei","raw_affiliation_strings":["Indiana University School of Medicine, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indiana University School of Medicine, Indianapolis, IN","institution_ids":["https://openalex.org/I4394709130"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018801649","display_name":"Jeffrey C.H. Goh","orcid":"https://orcid.org/0000-0002-1681-0484","observed_orcids":["https://orcid.org/0000-0002-1681-0484","https://orcid.org/0000-0003-3103-146X"]},"institutions":[{"id":"https://openalex.org/I2799393793","display_name":"Royal Brisbane and Women's Hospital","ror":"https://ror.org/05p52kj31","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I1302211766","https://openalex.org/I2799393793","https://openalex.org/I2801244131"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Jeffrey C. Goh","raw_affiliation_strings":["Royal Brisbane and Women's Hospital, Brisbane, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Royal Brisbane and Women's Hospital, Brisbane, Australia","institution_ids":["https://openalex.org/I2799393793"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042726718","display_name":"Michelle Margaret Vaughan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802773633","display_name":"Christchurch Hospital","ror":"https://ror.org/003nvpm64","country_code":"NZ","type":"healthcare","lineage":["https://openalex.org/I2802773633","https://openalex.org/I4405259026"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"Michelle Margaret Vaughan","raw_affiliation_strings":["Christchurch Hospital, Christchurch, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Christchurch Hospital, Christchurch, New Zealand","institution_ids":["https://openalex.org/I2802773633"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056466058","display_name":"Philip James Beale","orcid":"https://orcid.org/0000-0003-3628-4597","observed_orcids":["https://orcid.org/0000-0003-3628-4597"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Philip James Beale","raw_affiliation_strings":["Sydney Cancer Centre, Sydney, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sydney Cancer Centre, Sydney, Australia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110905391","display_name":"Meaghan Elizabeth Tenney","orcid":"https://orcid.org/0009-0000-1336-096X","observed_orcids":["https://orcid.org/0009-0000-1336-096X"]},"institutions":[{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Meaghan Elizabeth Tenney","raw_affiliation_strings":["University of Chicago Medical Center, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago Medical Center, Chicago, IL","institution_ids":["https://openalex.org/I4210087865"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111887253","display_name":"Julie K. Martyn","orcid":"https://orcid.org/0000-0002-6166-4519","observed_orcids":["https://orcid.org/0000-0002-6166-4519"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Julie Martyn","raw_affiliation_strings":["NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia","institution_ids":["https://openalex.org/I129604602"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002130583","display_name":"Dirkje Willemien Sommeijer","orcid":"https://orcid.org/0000-0001-7974-5045","observed_orcids":["https://orcid.org/0000-0001-7974-5045"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Dirkje Willemien Sommeijer","raw_affiliation_strings":["NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia","institution_ids":["https://openalex.org/I129604602"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103602352","display_name":"J. L. Mes\u00edas Iglesias","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102880","display_name":"Bionomics (Australia)","ror":"https://ror.org/01c6n0g60","country_code":"AU","type":"company","lineage":["https://openalex.org/I4210102880"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Jose Luis Iglesias","raw_affiliation_strings":["Bionomics Ltd., Thebarton, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bionomics Ltd., Thebarton, Australia","institution_ids":["https://openalex.org/I4210102880"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102731529","display_name":"David C. Bibby","orcid":"https://orcid.org/0000-0002-4123-6007","observed_orcids":["https://orcid.org/0000-0002-4123-6007"]},"institutions":[{"id":"https://openalex.org/I4210102880","display_name":"Bionomics (Australia)","ror":"https://ror.org/01c6n0g60","country_code":"AU","type":"company","lineage":["https://openalex.org/I4210102880"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"David C. Bibby","raw_affiliation_strings":["Bionomics Ltd., Thebarton, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bionomics Ltd., Thebarton, Australia","institution_ids":["https://openalex.org/I4210102880"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jeremy Simpson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102880","display_name":"Bionomics (Australia)","ror":"https://ror.org/01c6n0g60","country_code":"AU","type":"company","lineage":["https://openalex.org/I4210102880"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Jeremy Simpson","raw_affiliation_strings":["Bionomics Ltd., Thebarton, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bionomics Ltd., Thebarton, Australia","institution_ids":["https://openalex.org/I4210102880"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062839002","display_name":"Elizabeth E. Doolin","orcid":"https://orcid.org/0000-0002-8972-7315","observed_orcids":["https://orcid.org/0000-0002-8972-7315"]},"institutions":[{"id":"https://openalex.org/I4210102880","display_name":"Bionomics (Australia)","ror":"https://ror.org/01c6n0g60","country_code":"AU","type":"company","lineage":["https://openalex.org/I4210102880"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Elizabeth E. Doolin","raw_affiliation_strings":["Bionomics Ltd., Thebarton, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bionomics Ltd., Thebarton, Australia","institution_ids":["https://openalex.org/I4210102880"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011600094","display_name":"Corinne E. Williams","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210122680","display_name":"Hoosier Cancer Research Network (United States)","ror":"https://ror.org/02mtpb511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122680"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Corinne E. Williams","raw_affiliation_strings":["Hoosier Oncology Group, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hoosier Oncology Group, Indianapolis, IN","institution_ids":["https://openalex.org/I4210122680"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061757629","display_name":"Martin R. Stockler","orcid":"https://orcid.org/0000-0003-3793-8724","observed_orcids":["https://orcid.org/0000-0003-3793-8724"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Martin R. Stockler","raw_affiliation_strings":["NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia","institution_ids":["https://openalex.org/I129604602"]}]},{"author_position":"last","author":{"id":null,"display_name":"Australia New Zealand Gynaecological Oncology Group (ANZGOG)","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Australia New Zealand Gynaecological Oncology Group (ANZGOG)","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"31","issue":"15_suppl","first_page":"TPS5612","last_page":"TPS5612"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vascular-disrupting-agents","display_name":"vascular disrupting agents","score":0.8579999804496765},{"id":"https://openalex.org/keywords/tubulin-polymerization-inhibitors","display_name":"tubulin polymerization inhibitors","score":0.8379999995231628},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":0.9639999866485596},{"id":"https://openalex.org/keywords/primary-peritoneal-cancer","display_name":"primary peritoneal cancer","score":0.8360000252723694},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":0.9100000262260437},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":1.0},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.8539999723434448},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6269999742507935},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.9120000004768372},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.4129999876022339},{"id":"https://openalex.org/keywords/hog","display_name":"HOG","score":0.8040000200271606},{"id":"https://openalex.org/keywords/recist-1-1","display_name":"RECIST 1.1","score":0.7549999952316284}],"concepts":[{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.9520903825759888},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.9474637508392334},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8620579838752747},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.6904453635215759},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5981297492980957},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5767868757247925},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5762914419174194},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.5167773962020874},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.46050354838371277},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4445953965187073},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3858925402164459},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.350351482629776},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.29723185300827026},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2013.31.15_suppl.tps5612","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.tps5612","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.15_suppl.tps5612","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9922999739646912,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2478401716","https://openalex.org/W2898091448","https://openalex.org/W1966281277","https://openalex.org/W2475534444","https://openalex.org/W2121052942","https://openalex.org/W2890239618","https://openalex.org/W2247199816","https://openalex.org/W4244723474","https://openalex.org/W812207445","https://openalex.org/W2234133053"],"abstract_inverted_index":{"TPS5612":[0],"Background:":[1],"BNC105P":[2,18,44,66,88,163],"is":[3,101,221],"a":[4,9,47,198],"tubulin":[5],"polymerization":[6],"inhibitor":[7],"and":[8,29,40,85,166,206,210,304,312,315],"vascular":[10],"disrupting":[11],"agent":[12],"(VDA).":[13],"In":[14],"vivo":[15],"exposure":[16],"to":[17,20,37,112,122,140,184,227,283],"leads":[19],"selective":[21],"damage":[22],"of":[23,34,65,87,156,162,175,197,203,236,248,254],"tumor":[24,42],"vasculature":[25],"in":[26,89,94,188],"both":[27],"primary":[28,106,214],"metastatic":[30],"lesions,":[31],"causing":[32],"disruption":[33],"blood":[35],"flow":[36],"tumors,":[38],"hypoxia,":[39],"associated":[41],"necrosis.":[43],"also":[45,319],"has":[46,61],"direct":[48],"anti-proliferative":[49],"action":[50],"on":[51],"cancer":[52,56,91],"cells,":[53],"including":[54],"ovarian":[55,90,104],"cell":[57],"lines.":[58],"Pre-clinical":[59],"data":[60],"demonstrated":[62],"synergistic":[63],"activity":[64],"when":[67,92],"combined":[68],"with":[69,72,96,103,240,256],"platinum":[70,117,128,293],"or":[71,105,120,238,302],"gemcitabine,":[73],"supporting":[74],"the":[75,83,142,147,217,241,257,277],"proposed":[76],"study":[77,80,202,278],"design.":[78],"This":[79],"will":[81,137,170,177,195,271,318],"determine":[82,141],"safety":[84],"efficacy":[86],"used":[93,139],"combination":[95,149],"gemcitabine-carboplatin.":[97],"The":[98,173,191,213],"target":[99,280],"population":[100],"women":[102],"peritoneal":[107],"cancers":[108],"who":[109],"progressed":[110],"4":[111,121],"9":[113],"months":[114,124,298,301],"after":[115,125],"first-line":[116],"based":[118,129,294],"chemotherapy,":[119],"12":[123],"second":[126,308],"line":[127],"chemotherapy.":[130],"Methods:":[131],"A":[132],"single":[133],"arm":[134],"phase":[135,143,192,218,261],"I":[136],"be":[138,171,178,245,272,320],"II":[144,193,219,262],"dose":[145,153,160,174],"for":[146,216,276],"triplet":[148],"(3-6":[150],"subjects":[151],"per":[152],"level,":[154],"maximum":[155],"24":[157],"subjects).":[158],"Four":[159],"levels":[161],"(12-16":[164],"mg/m2)":[165,169],"gemcitabine":[167,205,209],"(800-1000":[168],"assessed.":[172],"carboplatin":[176,207,211],"set":[179],"at":[180],"AUC":[181],"4.":[182],"Enrolment":[183],"cohort":[185],"2":[186],"started":[187],"January":[189],"2013.":[190],"component":[194],"consist":[196],"2-arm,":[199],"randomized":[200],"(1:1)":[201],"BNC105P,":[204],"versus":[208],"alone.":[212],"endpoint":[215],"trial":[220,323],"objective":[222],"response":[223],"rate":[224],"(ORR,":[225],"according":[226,282],"RECIST":[228,284],"1.1":[229],"and/or":[230],"GCIG":[231],"CA125":[232],"criteria.":[233],"An":[234],"ORR":[235,253],"40%":[237],"more":[239],"experimental":[242],"regimen":[243,296],"would":[244],"considered":[246],"worthy":[247],"further":[249],"investigation,":[250],"assuming":[251],"an":[252],"20%":[255],"control":[258],"regimen.":[259],"110":[260],"participants":[263],"are":[264],"planned":[265],"(N":[266],"=":[267],"55/arm).":[268],"Treatment":[269],"allocation":[270],"balanced":[273],"using":[274],"minimization":[275],"site,":[279],"lesions":[281],"(present":[285],"vs.":[286,307],"absent),":[287],"progression":[288],"free":[289],"interval":[290],"from":[291],"last":[292],"chemotherapy":[295],"(<6":[297],"vs":[299],"6":[300],"more),":[303],"first":[305],"relapse":[306],"relapse.":[309],"Biomarker":[310],"(tissue":[311],"blood-borne)":[313],"sampling":[314],"PK":[316],"analysis":[317],"undertaken.":[321],"Clinical":[322],"information:":[324],"NCT01624493.":[325]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2016-08-23T00:00:00"}